Ask HopeStage to review this study with me
Study ID: NCT03465787. We help you review the study, but cannot decide medical eligibility.
CompletedNCT03465787
Lurasidone HCL for schizophrenia
This study is completed in South Korea. It is testing Lurasidone HCL for schizophrenia.
SchizophreniaOtherFrom 19 Years to 75 Years
Key information made simple
What is this study testing?
This study is testing whether Lurasidone HCL may be useful for adults experiencing schizophrenia.
What would participation involve?
Participants may receive Lurasidone HCL, complete questionnaires or follow-up assessments, attend study visits with the research team. The registry lists locations in South Korea.
Who is it mainly for?
This study appears to be mainly for adults with schizophrenia.
What should you check before joining?
Ask about the dose, safety monitoring, and possible side effects, whether there is a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.
Your next step
The official record suggests in-person participation through a research setting, with sites including Borame Medical Center in Seoul. Participation appears to involve a study treatment together with follow-up visits and routine safety or progress checks. The main fit is usually matching the main diagnosis and meeting the main study requirements, while common reasons not to take part include active substance or alcohol problems that could affect the results and safety concerns that need urgent care first. This is a later-stage study, which usually means a larger group and a closer look at how well the approach holds up.
Questions to ask before joining
- What are the exact eligibility criteria, and what could exclude someone?
- How many visits, assessments, or follow-ups are expected, and over what period?
- What risks, side effects, practical burdens, or alternatives should be understood first?
- Who should be contacted to confirm locations, timing, compensation, and next steps?
Things to check before joining
Study start dateStarted: April 9, 2018
- Recruitment status
- Completed
- Estimated enrollment
- Not clearly listed
- Sponsor
- Bukwang Pharmaceutical
- Sponsor type
- Pharmaceutical company
- Study type
- Other
- Intervention type
- Other / unclear
- Study phase
- Not clearly listed
- Locations
- South Korea
- Age range
- From 19 Years to 75 Years
- Official registry ID
- NCT03465787
- Official title
- A 6-week Study to Evaluate the Efficacy and Safety of Lurasidone HCL in Acutely Psychotic Patients With Schizophrenia
- Official source
- Official registry link
Want help reviewing this study?
Study ID: NCT03465787. We help you review the study, but cannot decide medical eligibility.
For you
Taking part may give access to a new approach being evaluated.
It requires regular visits and structured follow-up.
Requires travel, with in-person participation in South Korea.
Not medical advice
Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com
Questions about this study
What is this study trying to understand?
This study is exploring observational follow-up for people with schizophrenia. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.
Why is the study type not clearly categorized?
The study type is not clearly categorized in the public registry. Focus on the objective, required tasks, visits, any intervention, and eligibility criteria, then ask the study team to confirm.
Do I need to want to stop or reduce tobacco use to participate?
The public registry appears to mention tobacco, nicotine, alcohol, cannabis, or another addiction-related topic. Ask the study team whether you need to want to stop, reduce, already be abstinent, or simply meet use-related criteria. Eligibility must be confirmed by the study team.
What would I likely need to do?
The public registry does not clearly describe all participation steps. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.
What risks or points should I check?
The public registry does not make the main risk category clear. Ask the study team what activities are required, what could feel uncomfortable, how safety is monitored, and what happens if you want to stop. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.
Will I need to travel or attend in-person visits?
The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.
Who is behind this study?
This study is sponsored by Bukwang Pharmaceutical, which appears to be a pharmaceutical company. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.
Can I still join this study?
The registry indicates that this study is completed. It may still be useful for understanding the research, but you are unlikely to be able to join.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meExplore related studies
Other studies that may be relevant based on condition, country, or study type.
CompletedNCT01614899
A Phase III Study of SM-13496 (Lurasidone HCl) in people with Schizophrenia
This study is completed. It focuses on schizophrenia and currently lists study information in Japan, Malaysia, South Korea, and Taiwan.
CompletedNCT01051531
A Safety, Tolerability, and Treatment Response Study of Paliperidone Palmitate Administered to people with Schizophrenia
This study is completed in Australia, in New Zealand, in China, .... It focuses on schizophrenia.
CompletedNCT03345342
Paliperidone Palmitate 6-Month Formulation
This study is completed in the United States, in Australia, in France, .... It focuses on Schizophrenia.